Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered
Xconomy Boston — Gene editing biotech Beam Therapeutics raised $180 million in its initial public offering Wednesday after offering 48...
top of page
A L T I T U D E
Life Science Ventures
Companies in the News
Jan 9, 2020
eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-in-Class Inhibitors of eIF4E
SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators...
Jan 9, 2020
Omniome Closes $60 Million Series C Financing to Advance Novel Genomic Sequencing Platform
Company Raises $145 Million in Eighteen Months to Complete Development and Early Commercialization of Breakthrough DNA Sequencing...
Jan 6, 2020
Indigo closes $200M financing to support continued growth of its platforms, including Indigo Grain M
Indigo raises an additional $200M, comprised of $175M in convertible equity and $25M in debt, bringing its total capital raised to...
Nov 12, 2019
Gossamer Bio Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combi
Phase 1/2 trial ongoing with multiple patients dosed in GB1275 monotherapy dose escalation – GB1275 granted Orphan Drug Designation for...
Nov 5, 2019
Effector Therapeutics Initiates Phase 1/2 Safety and Efficacy Study of Zotatifin (EFT226) in Patient
Program addresses aggressive cancers with RTK (HER2, ERBB3, FGFR1, FGFR2) and KRAS mutations SAN DIEGO, November 5, 2019 — eFFECTOR...
Nov 5, 2019
Gritstone Oncology Announces Data on Novel Shared Tumor-Specific Neoantigens Identified by its EDGE
EMERYVILLE, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company...
Oct 28, 2019
Oncology Start-Up Nuvation Bio Closes $275 Million Series A Financing Led by Omega Funds
Biotechnology Veteran David Hung, M.D. Launches Stealth Start-Up Focusing on the Foremost Unmet Needs in Oncology Nuvation Bio's...
Oct 9, 2019
GSK and Lyell Immunopharma join forces to develop the next generation of cancer cell therapies
Collaboration will combine Lyell’s technologies with GSK’s pipeline of cell therapies and manufacturing capability Issued: London and San...
bottom of page